TABLE 3.
IFN-γ responses to P. falciparum-derived peptides in DNA-immunized volunteers
| Vaccine component | Peptide code | Predicted HLA restriction | Sequence | Residues | No. responders/no. tested (% positive responders) | Range of net SFCs/106 PBMCs (geomean) |
|---|---|---|---|---|---|---|
| Defined class I-restricted T epitopes | ||||||
| PfCSP | CSP.A2.386 | HLA-A2 supertype | GLIMVLSFL | 386-394 | 1/15 (6.7) | 70.8 |
| CSP.A2.319 | HLA-A2.1 | YLNKIQNSL | 319-327 | 2/15 (13.3) | 12-96 (30.3) | |
| CSP.B8.86 | HLA-B8 | LRKPKHKKL | 86-94 | 1/5 (20) | 22.5 | |
| PfSSP2/TRAP | SSP.A3.522 | A3 supertype | LLACAGLAYK | 522-531 | 1/19 (5.3) | 23.8 |
| PfEXP-1 | EXP.A2.2 | HLA-A2 supertype | KILSVFFLA | 2-10 | 1/15 (6.7) | 42.1 |
| EXP.A2.83 | HLA-A2 supertype | GLLGNVSTV | 83-91 | 3/15 (20) | 14-17 (15.2) | |
| PfLSA-1 | LSA1.A2.1655 | HLA-A2 | RLEIPAIEL | 1655-1663 | 2/15 (13.3) | 12-38 (21.5) |
| LSA1.A2.4 | HLA-A2 | ILYISFYFI | 4-12 | 1/15 (6.7) | 13-19 (15.3) | |
| LSA1.A3.94 | HLA-A3 supertype | QTNFKSLLR | 94-102 | 1/19 (5.3) | 17.5 | |
| LSA1.A3.105 | HLA-A3 supertype | GVSENIFLK | 105-113 | 2/19 (10.5) | 18-41 (26.9) | |
| LSA1.A3.11 | HLA-A3 supertype | FILVNLLIFH | 11-20 | 2/19 (10.5) | 16-20 (18.1) | |
| PfLSA-3 | LSA3.A2.981 | HLA-A2.1 | VLDKVEETV | 981-989 la26 | 1/15 (6.7) | 14.4 |
| LSA3.A2.113 | HLA-A2.1 | DLLEEGNTL | 113-121 la20 | 1/15 (6.7) | 16.9 | |
| Defined or potential class II-restricted T epitopes | ||||||
| PfCSP | CSP.DR/A2.1 | HLA-DR, A2 | MMRKLAILSVSSFLFVEALF | 1-20 | 3/31 (9.7) | 12-23 (17.9) |
| CSP.DR/A2.318 | HLA-DR, A2 | EYLNKIQNSLSTEWSPCSVT | 318-337 | 5/31 (16.1) | 13-69 (25.4) | |
| CSP.DR.363 | HLA-DR | DIEKKICKMEKCSSVFNVVNS | 363-383 | 1/31 (3.2) | 16.9 | |
| CSP.DR/A2.375 | HLA-DR, A2 | SSVFNVVNSSIGLIMVLSFLFLN | 375-397 | 8/31 (25.8) | 13-28 (21.0) | |
| PfSSP2/TRAP | SSP.DR.223 | HLA-DR | VKNVIGPFMKAVCVE | 223-237 | 2/31 (6.5) | 28-30 (29.0) |
| SSP.DR.527 | HLA-DR | GLAYKFVVPGAATPY | 527-541 | 4/31 (12.9) | 16-42 (25.2) | |
| SSP.DR.509 | HLA-DR | KYKIAGGIAGGLALL | 509-523 | 3/31 (9.7) | 17-39 (27.0) | |
| PfEXP-1 | EXP.DR.82 | HLA-DR | AGLLGNVSTVLLGGV | 82-96 | 3/31 (9.7) | 21-31 (25.7) |
| EXP.DR.71 | HLA-DR | KSKYKLATSVLAGLL | 71-85 | 10/31 (32.3) | 21-96 (34.0) | |
| PfLSA-1 | LSA1.DR.13 | HLA-DR | LVNLLIFHINGKIIKNS | 13-27 | 1/31 (3.2) | 27.9 |
| LSA1.DR.94 | HLA-DR | QTNFKSLLRNLGVSENIFLK | 94-113 | 2/31 (6.5) | 13-25 (16.5) | |
| LSA1.DR.84 | HLA-DR | LTMSNVKNVQTNFKSLLRNLGVS | 84-107 (T1) | 3/31 (9.7) | 19-22 (20.4) | |
| LSA1.DR.1813 | HLA-DR | NENLDDLDEGIEKSSEELSEEKI | 1813-35 (T3) | 3/31 (9.7) | 18-25 (22.5) | |
| LSA1.DR.1888 | HLA-DR | DNEILQIVKELSEKITKYFMKL | 1888-1909 (T5) | 3/31 (9.7) | 19-20 (19.1) | |
| PfLSA-3 | LSA3.II.142 | Potential | LLSNIEEPKENIIDNLLNNI | 142-161 (CT1) | 1/31 (3.2) | 27.5 |
| LSA3.II.200 | Potential | LEESQVNDDIFNSLVKSVQQEQQHNV | 200-225 (NRII) | 1/31 (3.2) | 13.8 |